FDA alignment de-risks the Phase 2 design for TNX-4800, a novel Lyme disease prophylactic with no currently approved alternatives. The stock may see a positive catalyst-driven move, but the long timeline to data (2028+ enrollment) and competition from Pfizer/Valneva's advancing vaccine candidate cap the upside. Monitor for final protocol submission and any financing or partnership announcements to fund the large Phase 2 trial.
Price Chart
Executive Summary
Tonix announced FDA alignment on the adaptive Phase 2 field study design for TNX-4800, a long-acting monoclonal antibody for seasonal Lyme disease prevention in adults. The FDA agreed on a 3,300-patient randomized placebo-controlled trial with a primary efficacy endpoint at six months. Manufacturing is on track for Q1 2027, with enrollment expected in the 2028 season.
Key Facts
- FDA Type C meeting minutes confirmed alignment on Phase 2 adaptive field study design for TNX-4800
- Study will enroll approximately 3,300 adult participants from Lyme-endemic areas over two seasons
- Randomized 1:1 to receive TNX-4800 450 mg SC or placebo, two doses three months apart
- Primary efficacy endpoint: Lyme disease prevention at six months after first dose
- Secondary endpoint: prevention at three months; safety evaluated over 52 weeks
- Manufacturing of investigational product on track for delivery to study sites in Q1 2027
- Company expects majority of participants enrolled in 2028, with possible extension to 2029 if attack rate is low
Financial Impact
Not specified
Risk Factors
- Phase 2 trial may fail to meet efficacy or safety endpoints
- Competition from Pfizer/Valneva Lyme disease vaccine (positive Phase 3 data announced March 2026) could limit market opportunity
- Enrollment delays or lower-than-expected attack rates could push timeline beyond 2029
- Tonix may need additional financing to complete the large Phase 2 study
- Early-stage pipeline asset with no near-term revenue contribution from TNX-4800
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-035741 |
| Exhibit: ex99-01.htm | 0001493152-26-035741 |
| Document: 0001493152-26-035741-index-headers.html | 0001493152-26-035741 |
| Document: 0001493152-26-035741-index.html | 0001493152-26-035741 |
| Document: 0001493152-26-035741.txt | 0001493152-26-035741 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $5.73 | awaiting T+20 | — | $5.39 (−5.93%) |
Oct 15, 2026 12d ago | 8-K | $6.42 | awaiting T+20 | — | $5.39 (−16.04%) |
Oct 2, 2026 24d ago | 8-K | $8.07 | awaiting T+20 | — | $5.39 (+33.21%) |
Sep 22, 2026 5w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.39 (−49.10%) |
Sep 8, 2026 7w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.39 (−59.04%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.39 (−57.19%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.39 (−57.19%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.39 (−49.48%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.39 (−48.02%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.39 (−53.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers